Pliant Therapeutics Inc (STU:9PT)
€ 12.5 -0.7 (-5.3%) Market Cap: 778.32 Mil Enterprise Value: 448.21 Mil PE Ratio: 0 PB Ratio: 2.37 GF Score: 36/100

Pliant Therapeutics Inc at Cowen Health Care Conference Transcript

Mar 08, 2023 / 06:30PM GMT
Release Date Price: €29.4 (+2.80%)
Ritu Baral
TD Cowen - Analyst

I'm covering analyst, Ritu Baral. And with us from Pliant, we have President and CEO, Bernard Coulie, as well as Chief Medical Officer, Ãric Lefebvre.

Bernard, Eric, thank you so much for joining us today, and congratulations on the Bexo Phase 2 IPF data that you've been rolling out over the past six-plus months. We're going to spend most of our time discussing that today, but it's rare to be able to discuss a Phase 2 dataset and focus -- and not focus on the degree of clinical meaningful benefit and whether it is or not versus just how would it can mean for patients. So we're going to start there.

Questions & Answers

Ritu Baral
TD Cowen - Analyst

Maybe a basic mechanistic question that we never got around to on the conference calls where we seem to run out of time, given the anti-fibrotic effect that you've seen spanning in vitro studies all the way into Phase 2 now, how do you see the potential effect driven by alpha v beta 6 versus alpha v beta 1? And is there any sort of interplay? Is there any sort of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot